Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Atopy and Frequency of Exacerbation in Chronic Obstructive Pulmonary Disease Patients

The Relation Between Atopy and Frequency of Exacerbation in Chronic Obstructive Pulmonary Disease Patients

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to abnormalities of airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction. The presence of non-fully reversible airflow obstruction (FEV1/FVC \< 0.7 post-bronchodilation) measured by spirometry confirms the diagnosis of COPD

Who May Be Eligible (Plain English)

Who May Qualify: - Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria Who Should NOT Join This Trial: - Patients with known allergic diseases before enrollment - Patients with associated other chronic respiratory disorders - Patients with significant comorbidities that could influence respiratory function. - Recent respiratory infections or use of systemic corticosteroids within the last month before enrollment. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria Exclusion Criteria: * Patients with known allergic diseases before enrollment * Patients with associated other chronic respiratory disorders * Patients with significant comorbidities that could influence respiratory function. * Recent respiratory infections or use of systemic corticosteroids within the last month before enrollment.

Treatments Being Tested

DIAGNOSTIC_TEST

Skin prick test

Skin Prick Test (SPT): Common allergens including pollen, dust mites, Pet dander and mold. Serum IgE Levels: Total IgE Peripheral blood eosinophil was defined as an eosinophil count ≥ 5%, Quality of Life Assessment: COPD Assessment Test (CAT)

Locations (1)

Mohamed AbdElmoniem
Al Mansurah, Egypt